Cargando…
Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients
Lung cancers are ranked third among the cancer incidence in France in the year 2020, with adenocarcinomas being the commonest sub-type out of ~85% of non-small cell lung carcinomas. The constant evolution of molecular genotyping, which is used for the management of lung adenocarcinomas, has led to t...
Autores principales: | Armon, Subasri, Hofman, Paul, Ilié, Marius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394288/ https://www.ncbi.nlm.nih.gov/pubmed/34440689 http://dx.doi.org/10.3390/cells10081920 |
Ejemplares similares
-
Thoracic SMARCA4-deficient undifferentiated tumor
por: Jiang, Jiapeng, et al.
Publicado: (2023) -
Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas
por: Urer, Halide Nur, et al.
Publicado: (2023) -
SMARCA4‐deficient lung tumour that presented with haemoptysis and progressed rapidly
por: Inoue, Mari, et al.
Publicado: (2020) -
TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma
por: Mehta, Anurag, et al.
Publicado: (2022) -
Clinical characteristics and prognostic analysis of SMARCA4‐deficient non‐small cell lung cancer
por: Liang, Xiyue, et al.
Publicado: (2023)